半刚性Memo 4D瓣环成形环二尖瓣修复的早期临床与超声结果:MANTRA研究
MANTRA子研究前瞻性收集17家国际中心166例使用Memo 4D行二尖瓣修复患者的30天临床与超声数据。30天死亡率为0.6%,NYHA分级与KCCQ-12评分显著改善,左室舒张末径和左房容积下降,二尖瓣反流显著减轻。
要点
- Memo 4D半刚性环修复二尖瓣30天死亡率0.6%,卒中、肾衰、心梗各0.6%。
- 术后NYHA分级改善,KCCQ-12评分从69.1升至83.9。
- 左室舒张末径从55.19mm降至52.70mm,左房容积从125.79ml降至91.51ml。
核心结论
- 使用Memo 4D行二尖瓣修复在早期与良好的临床和血流动力学结果相关。
研究设计与样本
- MANTRA为前瞻性、多中心、全球上市后伞式研究,本分析为其Memo 4D子研究,纳入2021年7月至2023年6月17家国际中心166例患者。
主要发现
- 30天死亡率为0.6%(1例),卒中、急性肾衰竭、心肌梗死各0.6%(各1例),30天内再次手术2例。
- NYHA分级明显改善,KCCQ-12汇总评分从术前69.1(SD=23.7)升至30天83.9(SD=15.7)。
- 左室舒张末径从术前55.19(SD=7.10)mm降至30天52.70(SD=3.76)mm,左房容积从125.79(SD=46.33)ml降至91.51(SD=37.20)ml。
- 二尖瓣反流在术后至30天随访显著减轻。
临床怎么用
- 对于原发性二尖瓣反流(包括Barlow病)患者,可考虑使用Memo 4D半刚性环行二尖瓣修复,早期结果良好。
局限性
- 本分析为初步30天结果, enrolment仍在进行中,缺乏长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Memo 4D is a semi-rigid ring with an exclusive saddle shape and progressive increased anteroposterior diameter. This preliminary analysis reports 30-day clinical and haemodynamic outcomes of the MANTRA Memo 4D sub-study. METHODS: MANTRA is an 'umbrella' prospective, multicentre, worldwide post-market study to collect real-life safety and performance data on the Corcym devices. Clinical and echocardiographic outcomes were gathered preoperatively, at discharge and each follow-up. KCCQ-12 questionnaires were collected preoperatively and at 30 days. Echocardiographic studies were performed per a predefined protocol and assessed by an independent core laboratory. RESULTS: In total, 166 patients (52, 31.3% female, mean age 60.7 ± 11.4 years) underwent mitral valve repair with Memo 4D in 17 international institutions between July 2021 and June 2023 (enrolment is still ongoing). Primary was the most common aetiology (157, 94.6%), of which 33 cases of Barlow's disease (19.9%); secondary mitral regurgitation was present in six cases (3.6%). Thirty-day mortality was 0.6% (1). One stroke event (0.6%), one acute kidney failure (0.6%), one myocardial infarction (0.6%) and two reoperations within 30 days were reported. Surgery marked improvement in the patient's NYHA class associated with a significant increase in KCCQ-12 summary score, from 69.1 (SD = 23.7) preoperatively to 83.9 (SD = 15.7) at 30 days. End-diastolic left ventricular diameters decreased from 55.19 (SD = 7.10) preoperatively to 52.70 (SD = 3.76) mm at 30 days, and left atrial volume decreased from 125.79 (SD = 46.33) preoperatively to 91.51 (SD = 37.20) ml at 30 days. Mitral regurgitation significantly reduced after the operation and up to 30-day follow-up. CONCLUSIONS: Mitral valve repair with Memo 4D is associated with good clinical and haemodynamic outcomes in the early period.MANTRA ClinicalTrials.gov number NCT05002543.
引用
- Dzemali O, Rodriguez Cetina Biefer H, Di Eusanio M, et al. Mitral valve repair with the semi-rigid Memo 4D annuloplasty ring: early clinical and echocardiographic outcomes from the MANTRA study. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 39666948. doi:10.1093/icvts/ivae208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。